Who is sponsoring NCT06824818?

NCT06824818 is sponsored by University of Chicago.

What condition does NCT06824818 study?

NCT06824818 studies Elderly, Prostate Cancer.

What drugs are being tested in NCT06824818?

Interventions: LHRH Agonist Therapy Discontinuation.

What is the status of NCT06824818?

NCT06824818 is currently RECRUITING.

Last reviewed 2025-09-29 · How we verify

A Feasibility Trial of LHRH Agonist Discontinuation in Elderly Prostate Cancer Patients

NCT06824818 NA RECRUITING

This study seeks to identify if it is feasible to stop Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Therapy in elderly men with prostate cancer. We hypothesize that elderly prostate cancer patients on long term androgen ablation with LHRH agonists will be permanently castrated and do not require ongoing LHRH agonist therapy. Participants will be monitored by testosterone testing throughout study.

Details

Lead sponsor	University of Chicago
Phase	NA
Status	RECRUITING
Enrolment	155
Start date	2026-06
Completion	2027-06

Conditions

Elderly
Prostate Cancer

Interventions

LHRH Agonist Therapy Discontinuation

Primary outcomes

feasibility of stopping LHRH agonist therapy — 12 months after discontinuing LHRH agonist therapy
Fraction of patients maintaining castrate testosterone levels

Countries

United States